Your session is about to expire
← Back to Search
Enpatoran for Lupus
Study Summary
This trial is testing M5049 to see if it is an effective and safe treatment for lupus over 24 weeks. It is a randomized, double-blind, placebo-controlled, adaptive and dose-ranging study, which means that participants are randomly assigned to either receive the drug or a placebo, and neither they nor the researchers know who is receiving which. The study will last 33 weeks and participants will visit the clinic every 2 or 4 weeks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have uncontrolled heart issues, lupus affecting my kidneys, or active brain disorders.I have had cancer before.I do not have uncontrolled seizures or other serious brain problems.I have active lupus with specific skin and organ involvement.I do not have any serious ongoing infections.I have skin conditions not related to lupus.My skin condition due to lupus is active and severe.I have an autoimmune disease that is not lupus.I have or had HIV, hepatitis B, or hepatitis C.I am on a steady dose of medication for lupus.
- Group 1: Cohort A: Enpatoran high dose
- Group 2: Cohort A: Enpatoran low dose
- Group 3: Cohort B (Part 1 + Part 2): Enpatoran high dose
- Group 4: Cohort A: Placebo
- Group 5: Cohort B (Part 2): Enpatoran low dose
- Group 6: Cohort B (Part 2): Enpatoran medium dose
- Group 7: Cohort A: Enpatoran medium dose
- Group 8: Cohort B (Part 1 + Part 2): Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are participating in this research endeavor?
"440 eligible subjects must partake in this experiment. These individuals can be recruited from multiple areas, such as Across the Life Span in Smithfield, North carolina and HMD Research, LLC in Orlando, Florida."
How many healthcare facilities have implemented this research endeavor?
"This clinical trial utilizes the services of 16 different medical institutions, such as Across the Life Span in Smithfield, HMD Research, LLC in Orlando and Jordan Valley Dermatology Center in West Jordan. Additionally there are other locations providing their expertise to this project."
Is there an eligibility criteria to partake in this clinical study?
"This investigation is accepting 440 subjects with systemic lupus erythematosus aged 18-75. Eligibility also depends on a number of other factors, as specified in the clinical trial protocol."
Does this inquiry still accept volunteers?
"Affirmative. Information on clinicaltrials.gov suggests that this medical experiment is presently enrolling participants, with 440 needed from 16 locations since it was first published on 3/31/2022 and recently edited on 10/17/2022."
Does the eligibility criteria of this trial extend to individuals over 55?
"To be eligible for the trial, patients must fall within the age range of 18 to 75. If a patient falls below 18 or is above 65, they will have access to either an alternative study with 18 participants or one that encompasses 106 individuals respectively."
To what extent is M5049 administered at a low dosage deemed secure for humans?
"Taking into account the caveat that M5049 low dose has yet to be proven effective, our team rated its safety at 2 due to Phase 2 trial data."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger